BioCentury
ARTICLE | Financial News

Roivant raises $1.1B in equity financing

August 9, 2017 9:56 PM UTC

Roivant Sciences GmbH (Basel, Switzerland) raised $1.1 billion in an equity financing led by SoftBank Vision Fund. Existing investor Dexcel Pharma participated.

Roivant focuses on in-licensing deprioritized compounds to form disease-focused subsidiaries. The company says the funds are intended to “accelerate the launch of new subsidiaries within and beyond the biopharmaceutical industry.”...

BCIQ Company Profiles

Roivant Sciences Ltd.